Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations (TIRASMUS)

This study has been completed.
Sponsor:
Information provided by:
Vejle Hospital
ClinicalTrials.gov Identifier:
NCT00827684
First received: January 22, 2009
Last updated: June 7, 2011
Last verified: June 2011

January 22, 2009
June 7, 2011
March 2009
January 2011   (final data collection date for primary outcome measure)
Objective response rates
Same as current
Complete list of historical versions of study NCT00827684 on ClinicalTrials.gov Archive Site
  • Progression free survival
  • Overall survival
  • Translational Research
  • Tolerability
  • Progression free survival
  • Overall survival
  • Translational Research
Not Provided
Not Provided
 
Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
Phase II Study of Temsirolimus and Irinotecan in Chemotherapy Refractory Patients With KRAS Mutated Metastatic Colorectal Cancer

The purpose of this study is to investigate the safety and efficacy of temsirolimus as a single drug, and of temsirolimus in combination with irinotecan in chemotherapy resistant patients with KRAS mutated colorectal cancer.

Chemotherapy resistance is a major challenge in metastatic colorectal cancer (mCRC), and EGFR inhibitors have been introduced as 3rd line treatment to chemotherapy refractory patients. However, it has recently been established that response to treatment with irinotecan and cetuximab is confined to patients with wtKRAS tumors. Therefore, downstream targets are being proposed as potential inhibitors of the EGFR signalling in tumours with KRAS mutations. mTOR is a central intracellular signalling molecule and a rational approach for potential reversion of chemotherapy resistance in these patients.

Preclinical data suggest that different solid tumors could respond to mTOR inhibitors and report on enhanced antitumor activity in combination with different traditional cytostatic drugs. Furthermore recent preclinical data suggest that mTOR inhibition may induce tumor reduction in colon cancer xenographs. Temsirolimus (CCI-779) has been widely investigated in different clinical settings and is presently registered for treatment of renal cell carcinomas. Furthermore, is has recently shown response in metastatic breast cancer patients, but at present there are no clinical data on efficacy or safety in metastatic colorectal cancer patients.

The present study aims at investigating the safety and efficacy of monotherapy temsirolimus and a combination of temsirolimus and irinotecan in chemotherapy resistant, KRAS mutated colorectal adenocarcinomas.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Primary Purpose: Treatment
Metastatic Colorectal Cancer
  • Drug: Irinotecan
  • Drug: Temsirolimus
  • Active Comparator: Response or stable disease
    will receive Temsirolimus
    Intervention: Drug: Temsirolimus
  • Experimental: Progression
    Will receive a combination of Temsirolimus and Irinotecan
    Interventions:
    • Drug: Irinotecan
    • Drug: Temsirolimus
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
June 2011
January 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically verified colorectal adenocarcinomas
  • Age > 18 years and < 70
  • Metastatic colorectal cancer refractory 5-FU, oxaliplatin and irinotecan containing treatment regimes
  • KRAS mutation detected by DxS kit in primary tumor or metastatic lesion.
  • Measurable disease according to RECIST
  • ECOG performance status 0, 1 or 2
  • Adequate renal, hepatic and haematological function
  • Normal serum cholesterol and triglycerides
  • Blood samples and available paraffin embedded tumor material for translational research studies
  • Fertile males and females (< 2 years after last period for women) must use effective birth control
  • Signed Informed consent

Exclusion Criteria:

  • Clinically significant heart disease, active severe infections or other concurrent disease
  • Other malignant diseases within 5 years of inclusion in the study, except basal cell squamous cell carcinoma of the skin and cervical carcinoma-in-situ
  • Prior radiotherapy within 30 days of treatment start
  • Other experimental therapy within 30 days of treatment initiation
  • Patients who are breast feeding, childbearing or of childbearing potential without using dual effective contraception
  • Clinical or radiological evidence of CNS metastasis
  • Completed any major surgery, excision biopsy or significant traumatic lesion ≥ 4 weeks from start of treatment and completed any minor surgery ≥ 1 week prior to start of treatment

    • Insertion of a vascular access device is not considered major or minor surgery from the viewpoint of protocol eligibility
    • Patients must have fully recovered from the procedure and have a fully healed incision
  • Planned radiation therapy against target-lesions
  • Patients with significant non-healing wounds or ulcers
  • History or evidence of thrombotic or hemorrhagic disorders

    • Significant haemorrhage (> 30 ml/bleeding episode in previous 3 months)
    • Haemoptysis (> 5 ml fresh blood in previous 4 weeks)
  • Patients on full-dose anticoagulation (e.g., warfarin) are eligible provided that both of the following criteria are met:

    • The patient has an in-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or is on a stable dose of low molecular weight heparin
    • The patient has no active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
  • Previous Cerebro-Vascular Accident (CVA), Transient Ischemic Attack (TIA) or Sub-Arachnoid Hemorrhage (SAH) within 12 months prior to randomization
  • No known or history of HIV seropositivity
  • The use of ACE inhibitors is not permitted during the study
  • Known allergy to temsirolimus, sirolimus, polysorbate 80 or included agents.
  • Agents with strong CYP3A4-inhibitory potential
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT00827684
2008-007665-22
Yes
Professor, MD, DMSc Andes Jakobsen, Dept. of Oncology, Vejle Hospital
Vejle Hospital
Not Provided
Study Chair: Anders Jakobsen, MD, DMSc Vejle Hospital
Principal Investigator: Karen-Lise G Spindler, MD, PhD Vejle Hospital
Vejle Hospital
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP